Its important to review their medical history to understand what toxicities they could potentially manage, whether its underlying hypertension or peripheral neuropathy relative to diabetes. Early in his career, Mr. Giusti worked as an executive for GE where he held a number of management positions with a wide range of responsibilities. These patients had several cycles of VRd with or without a transplant and then received lenalidomide maintenance. Ive learned how to manage my energy and put it towards things that matter most to me. Initially Diagnosed: 2002 This workshop will discuss trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development. Absence of high-risk DNA abnormalitiesaand She graduated from Stockton University with a degree in Public Health Administration, followed by an Accelerated Bachelors of Science in Nursing degree from Fairleigh Dickinson University. Gilmore is a longtime volunteer for Stanford. Etiam porta sem malesuada magna mollis euismod. Myeloma Click to explore ways that you can donate. Epub 2022 Mar 24. 36, from Acworth, GA Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. In your corner to support with training and fundraising tips leading up to race day! Now, the phase 3 CARTITUDE-4 trial is underway. It was difficult for Randi to believe that she had cancer, as she had to learn to recreate herself and was grateful to be alive. Originally, we could see when initial data were coming out at the planned interim analysis that there was a significant improvement in sCR with the quadruplet [regimen of daratumumab (Darzalex), lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Dara-VRd)] compared with the triplet regimen [RVd].1 We received the final analysis here at IMS 2022. Financial Disparities Affect Outcomes for Patients With Myeloma. Hearn Jay Cho, MD, PhD joined the MMRF as Chief Medical Officer (CMO). Wear more sunscreen and body glide than you think you need! In an interview with Targeted Oncology during the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma. Her diagnosis affected her in medicinal, environmental, holistic, mental, personal and spiritual ways. Nurse Practitioners/Physician's Assistants, 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates, Contemporary Concepts in Hematologic Oncology, Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice, Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer, | 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates, | Contemporary Concepts in Hematologic Oncology, | Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice, | Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer, Recent Advances in Multiple Myeloma: Highlights from the IMS 2022 Meeting and Beyond. Norwalk, CT 06851, The MMRF is a registered 501(c)(3) non-profit. At this time she was diagnosed with smoldering myeloma after receiving a second opinion. Researchers sought to determine whether adding daratumumab to lenalidomide and dexamethasone would improve outcomes in patients with newly diagnosed, transplant-ineligible MM. Currently, Dr. Pinizzotto is the named Chair of Obstetrics and Gynecology at Christiana Care Hospital, Newark, Delaware, and is also a trustee of the hospital. Before joining Citigroup, Ms. Gilman was the Director of Meetings, Client Relations and Incentives at Victorias Secret Beauty. Push Notifications: To opt out of receiving push notifications, please set your preferences within your device setting menu. WebOn November 8-9, 2022, the U.S. Food and Drug Administration (FDA) and the International Myeloma Society (IMS) will host a joint symposium, to provide a forum for open From 2011-2014 he was Executive Director, R&D Informatics and Head of Strategic Programs in AstraZenecas Research & Development Information Department where he led groups on Real World Evidence and Payer Evidence, Personalized Medicine and Biomarkers and Clinical Trials Design and Interpretation, dedicated to leveraging healthcare data for the development of ethical pharmaceuticals. In addition, we may transfer your Personal Data outside the EEA if the transfer is necessary to establish, exercise or defend legal claims or to protect your vital interests. He joined SAC in October 1999 as Chief Operating Officer. The 2023 edition will be the 23rd such conference. 2022 International Myeloma Society Conference | Blood Cancers Daratumumab-Based Quadruplet Demonstrates Efficacy in High-Risk Myeloma Subgroups. Cette adresse e-mail est protge contre les robots spammeurs. IMS 54, from Vermillion, SD in chemistry with a minor concentration in economics from Colgate University. Meaningful progression-free survival and safety elicited with isatuximab plus pomalidomide and dexamethasone treatment in real-world multiple myeloma population. Developing short term and long term treatment plans with her healthcare team, and allowing room for adjustment as needed has been a part of process. She is a certified translator, bilingual in Spanish, and is a member of the Oncology Nursing Society. Prior to founding CyberSource he held positions at Price Waterhouse, IBM, and McAfee Associates. She is chemotherapy certified and is currently in school to obtain her masters degree in nursing education. Do you think its a drug thats better-used upfront or in relapse? In 2013 he joined a technology startup called Vettery, where he helped to launch the brand and all of its communications while serving as the companys Chief Client Officer & lead brand strategist. function timestamp() { WebMultiple MyelomaTypes Plasma cell dyscrasias PCL-like MM Transplant-ineligible MM Chromosomal aberrations Risk MM-related mutations View all Types VIEW ALL A study of real-world outcomes of patient with relapsed or refractory multiple myeloma treated with isatuximab in now enrolling. Learn about why and how the tests are done and what the results mean. Those results are pretty practice changing. Current Diagnosis: Relapsed, Refractory. Autologous Stem Cell Transplantation (ACST), Friday, May 5, 2023, 1:00 PM-2:00 PM (ET), Multiple Myeloma Precursor Conditions, With Updates, Wednesday, April 5, 2023, 2:30 PM-3:30 PM (ET), BCMA-Targeted Bispecific Antibodies in Multiple Myeloma, Tuesday, March 21, 2023, 4:00 PM-5:00 PM (ET), Management of Patients Who Have Relapsed After One to Three Prior Lines of Therapy, With Updates, Wednesday, March 8, 2023, 1:00 PM-2:00 PM (ET), Focus on Treatments, Monitoring, and Maintenance for Newly Diagnosed Multiple Myeloma Patients, With Updates, Friday, February 17, 2023, 12:00 PM-1:00 PM (ET), From Diagnosis to Prognosis: Understanding Multiple Myeloma (A Guide for Newly Diagnosed Patients), With Updates, Tuesday, January 24, 2023, 4:00 PM-5:00 PM (ET), Treatment Options for Patients Who Have Relapsed After Three or More Lines of Therapy, With an Update on Bispecific Antibodies, Friday, December 2, 2022, 1:00 PM-2:00 PM (ET), Wednesday, August 17, 2022, 1:00 PM2:00 PM (ET), Management of Patients Who Have Relapsed After One to Three Prior Lines of Therapy, Wednesday, July 13, 2022, 2:00 PM3:00 PM (ET), Focus on Treatments, Monitoring, and Maintenance for Newly Diagnosed Multiple Myeloma Patients, 2-M less than or equal to 3.5mg/L and albumin greater than or equal to 3.5 g/dL, 2-M greater than or equal to 5.5mg/L and either, Values Indicating a More Favorable Prognosis, Beta 2-microglobulin (2-microglobulin or 2-M). All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub. WebRecognized for her excellence in myeloma research, Dr. Mateos received the Brian G.M. The International Myeloma Society is pleased to announce the launch of its half-day Novel Immune Therapies Educational Workshop being held in convenient locations across the globe in 2022. Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail, Program Chair Robert Z. Orlowski MD, PhD Elisabeth E. Manansanch, MD, 2-M<3.5mg/L and albumin 3.5 g/dL and The findings will be presented at the 19 th International Myeloma Society (IMS) Annual Meeting in Los Angeles from August 25 27, 2022. She is also the Chief Mission Officer of the MMRF. These changes will be effective immediately for new users of our Website. Previously Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc. where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. At an Around the Practice program hosted by CancerNetwork, experts led by Surbhi Sidana, MD, assistant professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy and the Myeloma Cellular Immunotherapy program lead at Stanford University School of Medicine in California, spoke about treatment options for patients with multiple myeloma following data presented at the 2022 International Myeloma Society Annual Meeting [IMS 2022]. document.getElementById('cloak53201').innerHTML += '' +addy53201+'<\/a>'; Michael brings nearly 15 years of strategic consulting and operational experience in the life sciences industry. There was a small number of patients who had relapsed from the MRD-SURE cohorts, but those were generally patients who had very high-risk diseases. Lisa was diagnosed with MGUS at age 28 - discovered during a routine physical exam showing high protein levels in her bloodwork, but she was otherwise asymptomatic. It has been a journey from day one, but I feel we are confident going forward. Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma. Acknowledging her strong leadership and broad achievements, Novartis selected Meryl to train and serve as a certified Executive Coach to senior executives, a position she held from May 2015 until her retirement at the end of June 2017. Promouvoir une culture de la paix. David earned a B.A. November 5th 2022. In addition, he is responsible for all the MMRF preclinical and translational activities. Myeloma Presented in a patient-friendly manner and viewable on iPads, tablets, and smartphones, these HITs bring to life and explain concepts that can sometimes be difficult for patients and caregivers to understand. All content on this site is intended for healthcare professionals only. LocoMMotion: a prospective, non-interventional, multinational Jul 1, 2022 Darcy Lewis OncologyLive Vol. Recognized for her excellence in myeloma research, Dr. Mateos received the Brian G.M. Facon T, Cook G, Usmani SZ, et al. The marathon is a victory lap, a celebration after all your training! Can you share data from the phase 2 GRIFFIN study [NCT02874742] that were presented at the IMS 2022 and your takeaways? Additionally, she is an independent Board Director for SHARE, a 40-year-old survivor-led organization based in New York City that provides support, information, and resources to women affected by breast and ovarian cancers. Kathy is the Henry & Allison McCance Family Senior Fellow at Harvard Business School, where she serves as Faculty Co-Chair of the HBS Kraft Precision Medicine Accelerator. Etre un lieu d'accueil, de dialogue et de rencontres entre les diverses composantes de la socit tchadienne. She had her first relapse in January of 2021, which was unexpected. Higher levels reflect more extensive disease and poor kidney function. Thank you to the funders of the Multiple Myeloma Hub. Please contact us. Here, she supports myeloma patients in a variety of ways from triaging calls, to educating patients on their myeloma, labs and test results, and coordinating with research and management to implement integral changed and streamline processes for access to new treatments. This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Significant Depth of Response Achieved in Relapsed Multiple Myeloma With Isa-Kd. Myeloma Earlier, he founded Ridge Computers, designer of the worlds first commercial reduced instruction set computing (RISC) minicomputer. Dealing with cancer at such a young age was shocking, challenging and unrelatable/lonely, but with a strong support system, cancer mentors, great doctors/treatment, The MMRF, a positive outlook, education, faith and perseverance she reached complete remission after transplant and lived a very 'new normal' life, still able to balance career, life, and her condition. The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. Adrian serves on the board of the Stanford Athletics Buck/Cardinal Club, which supports all varsity sports at Stanford University. He received his M.D. Prior to her career in nursing, she worked in marketing and advertising in the real estate industry for 4 years. Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker to the Commonwealths Science, Technology, Engineering and Math Advisory Council. In addition, she is a board member at Eisenhower Medical Center, Rancho Mirage, California, and also sits on the quality improvement committee. These patients underwent induction followed by autologous stem cell transplant followed by consolidation. Dr. Chos laboratory is investigating novel therapies for multiple myeloma in two areas. Durie Outstanding Achievement Award in 2019 and the IMS Bart Barlogie Clinical Investigator Award in 2022. Chief Operating OfficerSalesforce Essentials. Current Diagnosis: Smoldering Rodney Gilmore is an attorney in the California Bay Area and a longtime college football broadcaster. Dana has served on numerous portfolio company boards and is the Chairman of GAB Robins NA. Sidana: We saw recent publication in Leukemia looking at frail patients who were on the MAIA study and we saw similar benefit in terms of PFS and response rate.7 Do you ever consider not giving a frail patient a triplet regimen? TWITTER COVERAGE Kristen has been a registered nurse for a little over 20 years. Karen Dietz, JD, MBA, is the Chief Administrative Officer and General Counsel. However, relapses are common and multiple myeloma remains a difficult disease to treat, so the need for new therapies remains. Initially Diagnosed: 2014 Prior to joining the MMRF, Michael was an Associate Principal at IQVIA in the consulting services organization where he developed strategies for biopharma, medical device, and non-profit organizations to drive innovation and operational excellence across a diverse set of business challenges including R&D and launch strategy, commercial due diligence and portfolio optimization, and organizational effectiveness. She currently supports the MMRF CureCloud study initiative to assist patients interested in enrolling, collaborates with the clinical research team, and builds trusting relationships with multiple myeloma patients to empower them to learn more about their disease. Initially Diagnosed: 2013 from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco. WebAgenda; Session Session Details; Opening Remarks for the Smart Health Program Sessions (Audio Description version available)Dr. Susan Gregurick presents opening Any changes to these Disclosures will be effective upon the earlier of thirty (30) calendar days following our dispatch of an email notice to you or thirty (30) calendar days following our posting of notice of the changes on the Website. Myeloma He previously served as an ESPN studio analyst and a contributor to ESPN.com and ESPN The Magazine (out of print as of 2019). He remains an active grandfather to his two young grandsons and helps his daughter by babysitting them. Tom was appointed President of SAC Capital in July 2008. Previously Chris was VP of Business Development at SkylineDx, providing commercialization strategy for their oncology portfolio. She is currently working towards her masters degree in Healthcare Administration. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population. if (response == null || response.value.trim() == "") { Brittany earned her Bachelor of Science in Nursing at the University of Delaware, where she had the opportunity to be a student nurse for a private physician for over a year. Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to facilitate future drug development and improve patient outcomes. A recognized developer of diverse talent, The Healthcare Businesswomen Association honored Meryl with its prestigious Woman of the Year Award. WebAbstracts of the 19th International Myeloma Society Annual Meeting 25-27 August 2022 25-28 August 2022 Los Angeles, CA Publication of this abstract supplement is He currently serves as the Chairman of the Entertainment Law Initiative of the Grammy Foundation, a division of the National Academy of Recording Arts and Sciences, which focuses on legal education programs for aspiring entertainment attorneys. Andrews biggest challenge after receiving his diagnosis was educating himself on this disease. Prior to the MMRF, Mr. Giusti worked as a Chief Executive Officer, leader, executive and entrepreneur for over 30 years; he has founded, managed and led a variety of businesses. Durie Outstanding Achievement Award in 2019 and the IMS Bart Barlogie Clinical Investigator Award in 2022. Costello: Its important to understand their performance status because age is just a number. The addition of isatuximab to carfilzomib, lenalidomide, and dexamethasone led to a response rate in all 10 patients included in a safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial. Initially Diagnosed: MGUS 28, MM 30 Lori is also the Chairman of the board of DNA Diagnostics Center, a growing leader in private DNA testing services, where she guides overall strategy and governance for corporate growth. She received her nursing education in Ireland, and completed a bachelors of nursing degree at the University of Arkansas. We will respond to your request within a reasonable time frame. An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma. Under her leadership, the HBS Kraft Precision Medicine Accelerator convenes best-in-class leaders from science, business, and technology to identify and solve challenges slowing the advancement of precision medicine. For further support with Google Translate, visit Google Translate Help. He was Chairman and CEO for 16 years. Once submitted, a member of our team will contact you as soon as possible. Current Diagnosis: Relapsed, Refractory Andrew has kept a positive outlook and is self-motivating. Did they progress on a CD38 antibody, or did they get a CASSIOPEIA-style or GRIFFIN-style [regimen] where they got it for a total of 2.5 years and then discontinued? A list of these countries can be found here: Standard Contractual Clauses: The European Commission has adopted standard data protection clauses, which provide safeguards for personal data transferred outside of the EEA. She served on the Patient Council Committee at the Norwalk Hospital and is a member of the Oncology Nursing Society. Registration:https://www.eventcreate.com/e/fda-imsjointsymposium, More Meetings, SOHO 2023 Annual Meeting-Hybrid WebInternational Myeloma Society 2022 Annual Meeting Belantamab Mafodotin Yields Good Response Rate in Patients With Relapsed, Refractory Multiple Myeloma Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma Kathy has more than two decades of experience in the pharmaceutical industry, previously holding senior positions at G.D. Searle and Merck. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. From 1986 to 1993, Tom was in the operations and equity divisions of Goldman, Sachs & Co., becoming Vice President in 1991. Lisa relapsed after about 5 years, but her condition is currently stable. He also had scientific roles at Schering-Plough and the Sandoz Research Institute. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Recognized for her excellence in myeloma research, Dr. Mateos received the Brian G.M. Ms. Andrews is a member of the American Bar Association and the New York State Bar Association. in English Literature from the Catholic University of America and lives in Westport, CT with her husband and son. By contract: We will transfer your Personal Data outside the EEA if the transfer is necessary to the performance of a contract between you and MMRF, or if the transfer is necessary to the performance of a contract between MMRF and a third party, and the contract was entered into in your interest. P.O. She brings over 23 years of development experience to this position. Erin is the Manager of the Patient Navigation Center. Nicole has been a registered nurse for five years, specializing in oncology and palliative care. Treatments Received: bortezomib, dexamethasone, lenalidomide , carfilzomib , daratumumab, and pomalidomide. Durie Outstanding Achievement Award in 2019 and the IMS Bart Barlogie Conference We began to learn how important it is to follow an MRD end point for these individuals. If a patient is progressing on a CD38 antibody, Im not going to give another CD38 antibody. elems["ts"] = JSON.stringify(new Date().getTime()); WebThe term "functional cure" is used to describe myeloma cells that could be detectable but aren't causing relapse or myeloma progression. Previously he had served tenures as Vice President and Head of the Oncology Therapeutic Area at Amgen and Vice President and Head of Global Clinical Oncology Development at Novartis. In 2016, Kathy was namedFaculty Co-Chair of the Harvard Business School (HBS) Kraft Precision Medicine Accelerator, a $20 million program endowed by Robert Kraft and the Kraft Family Foundation. Under Steves leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX breast cancer and colon cancer assays and has maintained an 80% product development success rate. Karen has worked with the consortium sites and pharma companies to launch nearly 100 multi-center clinical trials including the first-ever myeloma platform trial, MyDRUG. Most recently, the World Economic Forum recognized Hugh and Sensity as a Technology Pioneer. She continues to maintain her super healthy lifestyle and practices good dietary habits. Initially Diagnosed: 2010 Increased Rates of Viral Infections in Multiple Myeloma. She was then sent to a local hematologist who did a bone marrow biopsy. Continued use of our Website, following notice of such changes shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes. Carmens experience leading up to her diagnosis was unique in that she did not present any symptoms and was diagnosed via pre-pregnancy bloodwork. RN, BSN, BA, OCN Patient Navigation Center. Prior to founding WSM Capital, Bill founded CyberSource Corporation in 1994. Earlier in his career, he was a bond trader and founded the Mortgage Finance Group. Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.
Anne has been named to the PharmaVoice 100, and represents the MMRF on a number of working groups and committees including the Direct-to-Patient (DTP) solutions team at the Harvard Business School (HBS) Kraft Precision Medicine Accelerator and the Cancer Support Community Frankly Speaking About Cancer: Multiple Myeloma National Advisory Board. Post-hoc analysis findings from phase 2 DREAMM-2 trial show no relationship between ocular conditions found at baseline in patients with relapsed or refractory multiple myeloma and ocular toxicity from belantamab mafodotin. For someone who does not necessarily meet that criteria, whats nice about the MAIA data is it incorporated all comersolder patients, those with high-risk or standard-risk diseaseand they had just remarkable outcomes. It started with pain in my hip that was quickly diagnosed as cancer. Im thrilled to be at this point in our lives to be able to help others. At Peloton, Lori drove business growth with strategy, brand marketing, communications, PR, social/digital media, consumer insights, data analytics, creative services, and community engagement. Her last 2 years at JTCC were spent as the Administrative Supervisor of the Myeloma Division. function timestamp() { He lives in New York City with his wife, Kathleen McCabe and their two daughters. Sinai Tisch Cancer Institute. } Sign up today and we'll help you stay informed. Rob Miani joined the MMRF team as Chief Financial Officer in 2016. In addition, she has been honored with the American Association for Cancer Research Centennial Medal for Distinguished Public Service and the Healthcare Businesswomens Associations Woman of the Year Award. An Oakland, CA native, Gilmore is a member of the Oakland Babe Ruth Baseball Hall of Fame. He is determined to continue his active hobbies. Susan Marvin, Chair of the Board of The Marvin Companies, was part of the third-generation management team in what is today a fourth-generation family owned and operated company.

Infosec Certifications, Articles I